The FDA-approved update adds phase 3 HYPERION data on adults diagnosed with PAH within the past year.
News|Articles|December 16, 2025
Repositioning GLP-1 Drugs for Neurologic Disease: Evidence, Advances, and Outlook
Author(s)Marco Meglio
Fact checked by: Patrick Campbell
GLP-1 medications are revolutionizing treatment for neurological conditions.
Advertisement
Advertisement
One of the most searched topics on Google in 2025 was GLP-1s, a class of medications traditionally used to treat
Related to this article
Philadelphia-area PAH specialists discuss real-world patient mismatch with trial criteria, drug sequencing, and insurance access barriers.
Arrowhead's ARO-DIMER-PA cut PCSK9 by 72% and APOC3 by 88% with single doses, driving LDL-C and triglyceride reductions in mixed hyperlipidemia.
George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.
Andrew Cutler, MD, says real-world MDD patients respond to adjunctive cariprazine like trial participants, with gains in mood and function within weeks.
Frances Lee, MD, on the stigma driving under-detection of ALD and its disproportionate rise in women and younger adults.
SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
EMBARQ-CSU1 and EMBARQ-CSU2 showed sustained reductions in urticaria, with the antibody meeting all primary and key secondary endpoints at Week 12.
Advertisement
Advertisement